A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
Completed · Phase 1, Phase 2 · NCT05827068
Conditions: Seasonal Influenza
At a glance
- Research payments reported, 2025
- $2,758
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 698
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1011.1 (biological), mRNA-1011.2 (biological), mRNA-1012.1 (biological), mRNA-1010 (biological), mRNA-1010.2 (biological), mRNA-1010.3 (biological)
- Dates
- Started 2023-03-27; completion 2023-11-20
- Results posted
- Yes
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls in healthy adult participants.
From ClinicalTrials.gov, last updated 2025-02-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $2,758 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Donald Eagerton, M.D. Endocrinology & Diabetes · Myrtle Beach, SC
- Michael W. Peterson, D.O. Dermatology · Spanish Fork, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Qcare Site Services Inc $2,072
- Trial Management Associates LLC $686
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.